Pan-Cancer Interrogation of MUTYH Variants Reveals Biallelic Inactivation and Defective Base Excision Repair Across a Spectrum of Solid Tumors Clinically relevant actionable mutations were identified ...
"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
GlobalData on MSN
Dizal’s phase III NSCLC trial of Zegfrovy meets primary endpoint
The open-label trial enrolled patients across 16 countries and regions in Europe, Asia, South America, and North America.
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...
EGFR mutation testing is crucial for NSCLC treatment, but global disparities exist in access to comprehensive molecular diagnostics. Third-generation inhibitors and combination regimens improve ...
The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...
Trends in Lung Cancer Incidence and Mortality (1990-2019) in the United States: A Comprehensive Analysis of Gender and State-Level Disparities A total of 7,413 tumor specimens were tested. The ...
Sunvozertinib achieved a statistically significant, clinically meaningful PFS advantage over platinum-based chemotherapy by ...
A pair of late-breaking trials, LAURA and ADRIATIC, promise practice-changing news in lung cancer. The targeted therapy osimertinib (Tagrisso, AstraZeneca) improved progression-free survival (PFS) by ...
In 2006, Diana Lindsay, who had never so much as held a cigarette, was diagnosed with stage 4 lung cancer. It had metastasized to both lungs, her brain and lymph nodes. Keith Eaton, MD, PhD, clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results